We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Sending Fewer Warning Letters Regarding Clinical Trials
FDA Sending Fewer Warning Letters Regarding Clinical Trials
August 9, 2006
Despite a recent flurry of FDA warning letters regarding clinical trials, a CTA analysis shows a steady decline in the number of warning letters sent to sponsors, clinical investigators and institutional review boards (IRBs) over the past year.